Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma
Prof. Sarah Alexander
Survival of children and adolescents with high-risk, mature B-cell non-Hodgkin lymphoma (B-NHL) is improved by the addition of rituximab to chemotherapy. The effect of rituximab on immune reconstitution after therapy has not been well described. A prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial found that children with high-risk mature B-NHL receiving chemotherapy with rituximab were at risk of prolonged hypogammaglobulinemia, although severe infections were rare. Strategies for immunoglobulin replacementand revaccination are needed
